Literature DB >> 21034673

FOXP3 as an X-linked tumor suppressor.

Lizhong Wang1, Runhua Liu, Mark Ribick, Pan Zheng, Yang Liu.   

Abstract

The FOXP3 gene was initially identified because its mutation caused lethal autoimmune diseases in mice and humans. Mice with heterozygous mutations of FoxP3 (mouse version of the FOXP3 gene) succumb to mammary tumors spontaneously, while those with prostate-specific deletions develop prostate intraepithelial neoplasia. Somatic mutations, deletion, and epigenetic inactivation of FOXP3 are widespread among human breast and prostate cancers. Unlike autosomal tumor suppressor genes that are usually inactivated by mutations in both alleles, X-linked FOXP3 mutations in cancer samples are usually heterozygous, with the wildtype allele selectively inactivated in cancer. This skewed X-inactivation suggests a new approach to reactivation of FOXP3 for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21034673      PMCID: PMC4500105     

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  41 in total

1.  Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX.

Authors:  E M Lange; H Chen; K Brierley; E E Perrone; C H Bock; E Gillanders; M E Ray; K A Cooney
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

2.  A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors.

Authors:  M I Edelson; C C Lau; C V Colitti; W R Welch; D A Bell; R S Berkowitz; S C Mok
Journal:  Oncogene       Date:  1998-01-15       Impact factor: 9.867

3.  X-inactivation profile reveals extensive variability in X-linked gene expression in females.

Authors:  Laura Carrel; Huntington F Willard
Journal:  Nature       Date:  2005-03-17       Impact factor: 49.962

4.  Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations.

Authors:  G Chenevix-Trench; J Kerr; T Hurst; Y C Shih; D Purdie; L Bergman; M Friedlander; B Sanderson; A Zournazi; T Coombs; J A Leary; E Crawford; A N Shelling; I Cooke; T S Ganesan; J Searle; C Choi; J C Barrett; S K Khoo; B Ward
Journal:  Genes Chromosomes Cancer       Date:  1997-02       Impact factor: 5.006

5.  Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas.

Authors:  M K Dodson; L C Hartmann; W A Cliby; K A DeLacey; G L Keeney; S R Ritland; J Q Su; K C Podratz; R B Jenkins
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

6.  Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome.

Authors:  T Krejsgaard; L M Gjerdrum; E Ralfkiaer; B Lauenborg; K W Eriksen; A-M Mathiesen; L F Bovin; R Gniadecki; C Geisler; L P Ryder; Q Zhang; M A Wasik; N Odum; A Woetmann
Journal:  Leukemia       Date:  2008-09-04       Impact factor: 11.528

7.  Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer.

Authors:  Sebastian Hinz; Laia Pagerols-Raluy; Hans-Heinrich Oberg; Ole Ammerpohl; Sandra Grüssel; Bence Sipos; Robert Grützmann; Christian Pilarsky; Hendrik Ungefroren; Hans-Detlev Saeger; Günter Klöppel; Dieter Kabelitz; Holger Kalthoff
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

8.  FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.

Authors:  Tao Zuo; Runhua Liu; Huiming Zhang; Xing Chang; Yan Liu; Lizhong Wang; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

9.  Potential role of the inactivated X chromosome in ovarian epithelial tumor development.

Authors:  P C Cheng; J A Gosewehr; T M Kim; M Velicescu; M Wan; J Zheng; J C Felix; K F Cofer; P Luo; B H Biela; G Godorov; L Dubeau
Journal:  J Natl Cancer Inst       Date:  1996-04-17       Impact factor: 13.506

10.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy.

Authors:  R S Wildin; F Ramsdell; J Peake; F Faravelli; J L Casanova; N Buist; E Levy-Lahad; M Mazzella; O Goulet; L Perroni; F D Bricarelli; G Byrne; M McEuen; S Proll; M Appleby; M E Brunkow
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

View more
  14 in total

1.  FOXP3 immunoregulatory gene variants are independent predictors of human papillomavirus infection and cervical cancer precursor lesions.

Authors:  Fernando Cezar-Dos-Santos; Rodolfo Sanches Ferreira; Nádia Calvo Martins Okuyama; Kleber Paiva Trugilo; Michelle Mota Sena; Érica Romão Pereira; Ana Paula Lombardi Pereira; Maria Angelica Ehara Watanabe; Karen Brajão de Oliveira
Journal:  J Cancer Res Clin Oncol       Date:  2019-06-08       Impact factor: 4.553

Review 2.  The dual role of the X-linked FoxP3 gene in human cancers.

Authors:  Margaret Redpath; Bin Xu; Leon C van Kempen; Alan Spatz
Journal:  Mol Oncol       Date:  2011-03-30       Impact factor: 6.603

3.  The role of FOXP3 rs3761548 and rs2294021 polymorphisms in pediatrics acute lymphoblastic leukemia: association with risk and response to therapy.

Authors:  Zahra Ghasemi; Kurosh Kalantar; Zahra Amirghofran
Journal:  Mol Biol Rep       Date:  2021-01-30       Impact factor: 2.316

4.  FOXP3 orchestrates H4K16 acetylation and H3K4 trimethylation for activation of multiple genes by recruiting MOF and causing displacement of PLU-1.

Authors:  Hiroto Katoh; Zhaohui S Qin; Runhua Liu; Lizhong Wang; Weiquan Li; Xiangzhi Li; Lipeng Wu; Zhanwen Du; Robert Lyons; Chang-Gong Liu; Xiuping Liu; Yali Dou; Pan Zheng; Yang Liu
Journal:  Mol Cell       Date:  2011-12-09       Impact factor: 17.970

5.  FOXP3-miR-146-NF-κB Axis and Therapy for Precancerous Lesions in Prostate.

Authors:  Runhua Liu; Bin Yi; Shi Wei; Wei-Hsiung Yang; Karen M Hart; Priyanka Chauhan; Wei Zhang; Xicheng Mao; Xiuping Liu; Chang-Gong Liu; Lizhong Wang
Journal:  Cancer Res       Date:  2015-02-23       Impact factor: 12.701

6.  FOXP3 Controls an miR-146/NF-κB Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells.

Authors:  Runhua Liu; Cong Liu; Dongquan Chen; Wei-Hsiung Yang; Xiuping Liu; Chang-Gong Liu; Courtney M Dugas; Fei Tang; Pan Zheng; Yang Liu; Lizhong Wang
Journal:  Cancer Res       Date:  2015-02-23       Impact factor: 12.701

7.  Skp2 is a promising therapeutic target in breast cancer.

Authors:  Zhiwei Wang; Hidefumi Fukushima; Hiroyuki Inuzuka; Lixin Wan; Pengda Liu; Daming Gao; Fazlul H Sarkar; Wenyi Wei
Journal:  Front Oncol       Date:  2012-01-04       Impact factor: 6.244

8.  Investigation of FOXP3 genetic variations at positions -2383 C/T and IVS9+459 T/C in southern Iranian patients with lung carcinoma.

Authors:  Maryam Fazelzadeh Haghighi; Mohammad Ali Ghayumi; Farzane Behzadnia; Nasrollah Erfani
Journal:  Iran J Basic Med Sci       Date:  2015-05       Impact factor: 2.699

9.  Forkhead box P3 regulates ARHGAP15 expression and affects migration of glioma cells through the Rac1 signaling pathway.

Authors:  Zhen Sun; Biao Zhang; Chen Wang; Tao Fu; Lianling Li; Qiaoli Wu; Ying Cai; Jinhuan Wang
Journal:  Cancer Sci       Date:  2017-01-23       Impact factor: 6.716

10.  Silencing of Foxp3 delays the growth of murine melanomas and modifies the tumor immunosuppressive environment.

Authors:  Moisés A Franco-Molina; Diana F Miranda-Hernández; Edgar Mendoza-Gamboa; Pablo Zapata-Benavides; Erika E Coronado-Cerda; Crystel A Sierra-Rivera; Santiago Saavedra-Alonso; Reyes S Taméz-Guerra; Cristina Rodríguez-Padilla
Journal:  Onco Targets Ther       Date:  2016-01-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.